R&D expense revenue share of selected Chinese pharma companies 2021-2022
In 2021, the Chinese pharmaceutical companies invested between 1.27 and 12.63 percent of their sales revenue in research and development. That year, Livzon Pharmaceutical Group spent around 1.5 billion yuan on R&D, accounting for 12.63 percent of its sales revenue.